Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

A girl with a solitary red bulla

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients Patrizia Weber, MD, S. Morteza Seyed Jafari,

Facial adenocarcinoma treated with intra-arterial chemotherapy

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Psoriasis: Latitude does make a difference

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Pediatric teledermatology: Observations based on 429 consults

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Applying for dermatology residency is difficult and expensive

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Reply to: “A note on normality”

Alopecia areata Journal of the American Academy of Dermatology

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Improvement of Darier disease with diclofenac sodium 3% gel

Volume 4, Issue 7, Pages (August 2018)

Appearance of lentigines in psoriasis patients treated with apremilast

Medicaid acceptance among pediatric dermatologists

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families Lucy Y. Liu,

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Photosensitive lichenoid drug eruption to capecitabine

Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals Cynthia Haddad, PharmD, MSc, Odette Berline.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2) Jeffrey Crowley, MD, Diamant Thaçi, MD, Pascal Joly, MD, Ketty Peris, MD, Kim A. Papp, MD, PhD, Joana Goncalves, MD, Robert M. Day, PhD, Rongdean Chen, PhD, Kamal Shah, MD, Carlos Ferrándiz, MD, Jennifer C. Cather, MD Journal of the American Academy of Dermatology Volume 77, Issue 2, Pages 310-317.e1 (August 2017) DOI: 10.1016/j.jaad.2017.01.052 Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 A, Percentage of weight change from baseline over time. B, Percentage of patients exhibiting >5% weight loss by apremilast-exposure period (0 to ≤52 weeks and 0 to ≥156 weeks). C, Percentage of patients exhibiting >5% weight loss from baseline by body mass index category (overall, <25, ≥25 to <30, and ≥30). EOP, End of phase; n/m, number of patients with weight change divided by number of patients with sufficient data. *m includes all patients who received apremilast 30 mg twice daily regardless of when apremilast exposure started (week 0 or week 16). Represents all patients who experienced weight loss at anytime during the study; some patients experienced weight loss during both study periods. Journal of the American Academy of Dermatology 2017 77, 310-317.e1DOI: (10.1016/j.jaad.2017.01.052) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions